Paragon Health Institute Icon White

Biden Decides to ‘March In’ on Drug Patents

Biden March In Drug Patents
Director at Public Health and American Well-Being Initiative
Joel M. Zinberg, M.D., J.D. is the Director of the Public Health and American Well-Being Initiative at Paragon Health Institute, and a senior fellow with the Competitive Enterprise Institute. A native New Yorker, he recently completed two years as General Counsel and Senior Economist at the Council of Economic Advisers in the Executive Office of the President.

Apparently not content with destroying the pharmaceutical industry slowly by phasing in price controls, the Biden administration plans to speed up the process. The administration proposed last week a policy framework that allows government agencies to “march in” if prices are too high, requiring a drug’s patent holder to license its invention to other companies. While the administration claims that seizing patents will promote competition and lower drug prices, it will do neither. It will stifle pharmaceutical innovation and harm Americans’ health.

March-in rights were created in a 1980 law sponsored by Sens. Birch Bayh and Bob Dole, which allowed universities, nonprofits, and small businesses to retain ownership of patents for inventions discovered with the aid of federal funding. This ensured those inventions could be developed and made available to the public.

Before the Bayh-Dole Act, the government owned federally funded inventions and granted only nonexclusive licenses to developers. Few companies were willing to invest the money and time to transform a scientific discovery into a practical product unless they could own the discovery and exclude others from using it.

The full article can be found in The Wall Street Journal.

Related Content


Sign up now for your health policy updates.

This field is for validation purposes and should be left unchanged.